Zenyaku Kogyo Co., Ltd. develops dermatological and anti-cancer drugs. Its product includes Rituxan™, an anti-CD20 antibody for the treatment of B-cell Non-Hodgkin's Lymphoma. The company also develops OTC drugs. Zenyaku Kogyo Co., Ltd. was founded in 1950 and is based in Tokyo, Japan.
Founded in 1950
Anthera Pharmaceuticals, Inc. Enters into License Agreement with Zenyaku Kogyo Co., Ltd
Dec 16 14
On December 11, 2014, Anthera Pharmaceuticals Inc. entered into a license agreement with Zenyaku Kogyo Co., Ltd. pursuant to which the company granted Zenyaku an exclusive license to certain patent rights, know-how and other intellectual property relating to blisibimod. Under the agreement, Zenyaku obtained exclusive rights to develop, use, sell, have sold, offer for sale and import blisibimod and any related products containing any of blisibimod's binding domains, including but not limited to any pegylated blisibimod binding domain, certain rights to grant sublicenses and an option to expand the territory of the license to include China, Singapore, Taiwan, Philippines, Thailand, Malaysia, Vietnam, Indonesia and South Korea. The licensed patent rights include all patents controlled by Anthera or its affiliates relating to blisibimod, including those licensed to Anthera under that certain License Agreement dated December 18, 2007 between Anthera and Amgen Inc. as amended October 16, 2009 and November 26, 2014. Anthera retained the right to practice and grant licenses relating to blisibimod technology in all areas outside of the licensed territory, to manufacture and have manufactured compounds and products relating to blisibmod anywhere in the world and to conduct or have conducted clinical trials and other studies of compounds and products relating to blisibmod anywhere in the world. The development activities of both Anthera and Zenyaku will be overseen by a joint development committee. Under the terms of the License Agreement, Zenyaku assumes sole responsibility for the sale, marketing, promotion and commercialization of products relating to blisibimod in the licensed territory, and is obligated to use commercially reasonable efforts to market, promote, sell and commercialize licensed products in such territory.